Boxin

Boxin Biopharma is a clinical-stage biotechnology company based in Suzhou, China, dedicated to developing next-generation CAR-T cell therapies for solid tumors and hematological cancers. The company utilizes its proprietary armored CAR-T technology to enhance the persistence and efficacy of T-cells within the challenging immunosuppressive environments of solid tumors. Its lead candidate, BX-G3-01, targets Glypican-3 (GPC3) for the treatment of advanced hepatocellular carcinoma and is currently in Phase 1 clinical trials. Boxin's pipeline also includes programs targeting Claudin 18.2 and Mesothelin, aiming to address significant unmet medical needs in gastrointestinal and other solid malignancies. The company is supported by prominent venture capital firms and operates out of the Suzhou Biobay industrial park.